Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients

Clinical Microbiology and Infection

Volumn 13, Issue 12, 2007, Pages 1204-1206

  Saito, R ^a   Okugawa, S ^a   Kumita, W ^b   Sato, K ^b   Chida, T ^b   Okamura, N ^b   Moriya, K ^a   Koike, K ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Epidemiology; Extended spectrum lactamases; Fluoroquinolones; Proteus mirabilis; Risk factors; Urinary tract infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEPHEM DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NALIDIXIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; SULTAMICILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME SYNTHESIS; FEMALE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; URINALYSIS; URINE CATHETER;

PROTEUS MIRABILIS;

EID: 35848968039     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01826.x     Document Type: Article

References (12)

1. Richard P, Delangle MH, Raffi F et al. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32: 162-166.
2. Hyle EP, Lipworth AD, Zaoutis TE et al. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis 2005; 40: 1317-1324.
3. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-478.
4. Hernandez JR, Martinez-Martinez L, Pascual A et al. Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J Antimicrob Chemother 2000; 45: 407-408.
5. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: Risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005; 49: 2598-2605.
6. Kim JY, Park YJ, Kim SI et al. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother 2004; 54: 1144-1147.
7. Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-1294.
8. Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D et al. Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004; 10: 72-75.
9. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
10. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-A7. Wayne, PA: CLSI, 2006.
11. Yagi T, Kurokawa H, Shibata N et al. A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184: 53-56.
12. Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol 2004; 42: 5715-5721.